Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1643 1645 1646
This examiner grants 55% of resolved cases
Hong Sang is an examiner in Tech Center 1600 and Art Unit 1643. The examiner has a record of 931 resolved cases. The allowance rate for these cases is 55.0 percent. This 55.0 percent rate provides a benchmark for practitioners to evaluate the likelihood of a successful outcome in this technical area.
The interview lift for this examiner is 62.4 percent. This 62.4 percent lift indicates that conducting an interview is a highly effective strategy for improving the chances of allowance. The median days to allowance is 1273. This 1273-day figure helps practitioners estimate the duration of the prosecution process in Art Unit 1643. The 931 resolved cases offer a stable basis for these statistical observations in Tech Center 1600.
Practitioners can use the 1273 median days to allowance to manage their dockets and client expectations. The 55.0 percent allowance rate is a key factor in evaluating the examination landscape. Additionally, the 62.4 percent interview lift highlights the value of verbal advocacy in resolving outstanding issues with the examiner.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19418900 | METHODS OF TREATING HIGH RISK MULTIPLE MYELOMA | Final Rejection | Janssen Biotech, Inc. |
| 17774685 | Anti-TIGIT Antibodies and Uses Thereof | Non-Final OA | Merck Patent GmbH |
| 17808402 | ANTIBODIES AND METHOD OF PRODUCING ANTIBODIES | Non-Final OA | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 18549844 | GENERATION OF HUMAN PEANUT ALLERGEN-SPECIFIC IGE MONOCLONAL ANTIBODIES FOR DIAGNOSTIC AND THERAPEUTIC USE | Non-Final OA | VANDERBILT UNIVERSITY |
| 18443878 | METHODS OF TREATING MULTIPLE MYELOMA | Non-Final OA | Sanofi-Aventis U.S. LLC |
| 18550484 | METHODS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND COMBINATIONS WITH BISPECIFIC ANTIBODIES | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18477584 | Enhancing Activity of CAR T Cells by Co-Introducing a Bispecific Antibody | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18182676 | Expansion Of Peripheral Blood Lymphocytes (PBLS) From Peripheral Blood | Final Rejection | Iovance Biotherapeutics, Inc. |
| 18503107 | M971 CHIMERIC ANTIGEN RECEPTORS | Non-Final OA | The United States of America,as represented by the Secretary,Department of Health and Human Services |
| 18502993 | M971 CHIMERIC ANTIGEN RECEPTORS | Non-Final OA | The United States of America,as represented by the Secretary,Department of Health and Human Services |
| 16761183 | TEST KITS AND ASSAYS | Non-Final OA | InsituGen Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy